MaxCyte Stock

MaxCyte Equity Growth

The Year-over-Year Equity Growth of MaxCyte (MXCT) as of Aug 11, 2026 is -11.16 %. In the previous year, Year-over-Year Equity Growth was -8.60 % — a change of 29.86% (lower).

Equity Growth

-11.16 %

YoY

29.86%

Last updated:

Year-over-Year Equity Growth of MaxCyte is 2026 -11.16 % . Year-over-Year Equity Growth of MaxCyte was 2025 -8.60 % . It decreases by 29.86% lower compared to the previous year.
Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Year-over-Year Equity Growth of MaxCyte is -11.16 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth MaxCyte since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's MaxCyte historically and in real time.

Access this data via the Eulerpool API

Growth — MaxCyte

All Key Metrics — MaxCyte